Hookipa stock surges 46% on license deal with Roche for immunotherapy

Oct. 20, 2022 7:56 AM ETHOOKIPA Pharma Inc. (HOOK), RHHBY, RHHBFBy: Ravikash, SA News Editor3 Comments

Roche Headquarters

Rafael_Wiedenmeier/iStock Unreleased via Getty Images

Roche (OTCQX:RHHBY) (OTCQX:RHHBF) signed a license agreement with Hookipa Pharma (NASDAQ:HOOK) to develop immunotherapy HB-700 for KRAS-mutated cancers and a second undisclosed novel arenaviral immunotherapy.

Under the agreement, Hookipa will receive $25M upfront. The Swiss pharma giant will have the option

Recommended For You

Comments (3)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.